BioCentury
ARTICLE | Financial News

DMD play Exonics raises $40M series A

November 8, 2017 10:24 PM UTC

Exonics Therapeutics Inc. (Boston, Mass.) raised $40 million in a series A round from The Column Group. The company is developing its preclinical CRISPR technology to treat Duchenne muscular dystrophy.

The company launched in February with $5 million from CureDuchenne (see BioCentury, March 2)...

BCIQ Company Profiles

Exonics Therapeutics Inc.